Introduction: A key aspect of scientific reliability includes replicability, that is, obtaining consistent results when an experiment is repeated. In embryo-fetal developmental toxicity (EFDT) studies, replicability can be assessed using in vitro models, targeted in vivo studies, and/or the second species study. This work assesses the replicability of whole-animal studies using historic rat data.
Methods: Data for two endpoints from five full studies were downloaded from the National Toxicology Program (NTP) website. Each full group was divided into two replicate sets (based on odd/even and top/bottom animal order) to evaluate within-study replicability. Analyses included summary statistics, scatter plots, a modified Levene's test for homogeneity of variances, and Cohen's d to assess effect sizes.
Results: Replicate means deviated from the original study by only 0.4%-3.7% and differed by ≤ 7% between replicates (with differences < 5% in 87% of groups). Coefficients of variation (CV%) were generally consistent across subgroups, with few above 10%. Variance testing revealed significant differences in two of the five studies, and one study exhibited opposite fetal weight effects in the odd/even subgroup only. Evaluations of adjusted maternal weight gain were comparable across subgroups.
Conclusions: The observed 5%-7% differences between these idealized replicates may represent the lower bound for acceptable variability when merging replicate data sets. This work lays the groundwork for more robust evaluations of replicability in EFDT studies and may inform future regulatory guidance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bdr2.2461 | DOI Listing |
Birth Defects Res
March 2025
Independent Teratologist, Retired, Philadelphia, Pennsylvania, USA.
Introduction: A key aspect of scientific reliability includes replicability, that is, obtaining consistent results when an experiment is repeated. In embryo-fetal developmental toxicity (EFDT) studies, replicability can be assessed using in vitro models, targeted in vivo studies, and/or the second species study. This work assesses the replicability of whole-animal studies using historic rat data.
View Article and Find Full Text PDFReprod Toxicol
March 2025
Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China; Beijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing 100176, China; Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China. Electronic address:
SCTV01E, a novel SARS-CoV-2 tetravalent protein vaccine containing recombinant spike proteins of Alpha (B.1.1.
View Article and Find Full Text PDFReprod Toxicol
March 2025
Center for Disease Control and Prevention of Guangdong Province, Guangzhou 511430, China. Electronic address:
Monascus red (MR) is widely used as a natural food colorant and preservative in East Asia. However, the potential effects of MR during pregnancy remains unknown. In this study, MR was administrated to Sprague-Dawley (SD) rats at doses of 0, 0.
View Article and Find Full Text PDFInt J Parasitol Drugs Drug Resist
January 2025
GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; Institut de Nutrició i Seguretat Alimentària (INSA), Universitat de Barcelona, Barcelona, Spain; German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessmen (BfR), Berlin, Germany. Electronic address:
Background: Malaria during pregnancy implies a high risk for the mother and the developing child. However, the therapeutic options for pregnant women have historically been very limited, especially during the first trimester of pregnancy due to potential adverse effects on embryo-fetal development. Recently, there has been great controversy regarding these potential embryo-fetal adverse effects because the results of rodent studies were not in accordance with the clinical data available, and finally the WHO has changed the recommendations for pregnant women with uncomplicated P.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Drug Safety Research and Development, Pfizer Research & Development, Pearl River, NY 10965, USA.
: Respiratory syncytial virus (RSV) infections usually cause mild, cold-like symptoms in most people, but are a leading infectious disease causing infant death and hospitalization and can result in increased morbidity and mortality in older adults and at-risk individuals. Pfizer has developed Abrysvo, an unadjuvanted bivalent recombinant protein subunit vaccine containing prefusion-stabilized fusion (F) proteins representing RSV A and RSV B subgroups (RSVpreF). It is the only RSV vaccine approved for both maternal immunization to protect infants and active immunization of older adults (≥60 years) and 18-59-year-old individuals with high-risk conditions for prevention of RSV disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!